Determinants of induction-to-expulsion time and adverse maternal outcomes of second trimester medical abortion in Amhara Region, Ethiopia: Prospective follow-up study

Eyasu F. Yitina, Getasew S. Mihrete, Mequanint M. Bicha, Balemlay S. Andualem, Nigat A. Addis, Solomon M. Abebe, Lemi B. Tolu, Ayenew M. Lakew

Abstract

Second-trimester medical abortion (STMA) accounts for 20–40% of abortions in Ethiopia and is associated with risks including uterine rupture, hemorrhage, infection, incomplete abortion, and prolonged hospitalization. This multicenter prospective study included 617 women undergoing STMA in three referral hospitals in the Amhara region from January to October 2024. Induction to-expulsion time and associated factors were analyzed using Cox proportional hazard modeling. Median fetal and placental expulsion times were 10 and 10.5 hours, respectively, with an 81.2% complete expulsion rate. Prolonged expulsion was associated with higher gestational age, wider misoprostol dosing intervals, and younger maternal age. Reported complications included vaginal bleeding (34.8%), pain (44%), diarrhea (24.1%), vomiting (24%), fever (11.5%), infection (2.4%), incomplete abortion (19.8%), cervical tear (0.49%), and uterine rupture (0.16%). optimizing misoprostol regimens, improving pain management, strengthening follow-up, and ensuring surgical readiness are essential to enhance STMA safety and effectiveness.

Full Text:

PDF

References

Health EMo. MANAGEMENT PROTOCOL ON

SELECTED OBSTETRICS TOPICS FOR

HOSPITALS. December ,2020 G.C.

McGrawHill. Williams OBSTETRICS. 2022;26

THEDITION. chapter 9 (prenatal care).

Organization WH. Safe abortion: technical and policy

guidance for health systems: World Health

Organization; 2003.

Organization WH. Medical management of abortion: World

Health Organization; 2022.

Bearak J, Popinchalk A, Ganatra B, Moller AB, Tunçalp Ö,

Beavin C, Kwok L and Alkema L. Unintended

pregnancy and abortion by income, region, and the

legal

status

of abortion: estimates from a

comprehensive model for 1990-2019. The Lancet

Global health. 2020;8(9):e1152-e61.

Bebbington MW, Kent N, Lim K, Gagnon A, Delisle MF,

Tessier F and Wilson RD . A randomized controlled

trial comparing two protocols for the use of

misoprostol in midtrimester pregnancy termination.

American journal of obstetrics and gynecology.

;187(4):853-7.

Organization WH. Trend in maternal mortality: 1990 to

: WHO, UNICEF, UNFPA and The World Bank

estimates. 2012.

Cunningham F LK, Bloom S, Spong CY, Dashe J. Williams

obstetrics. Mcgraw-hill New York, NY, USA2014.

Cunningham FG, Leveno, KJ, Bloom SL, Dashe JS,

Hoffman BL, Casey BM and Spong CY. Williams

Obstetrics, 25th Edition. New York: McGraw-Hill

Education; 2018.

Education M-H. Williams GYNECOLOGY2020.

Bijma HH, van der Heide A, Wildschut HI. Decision

making after ultrasound diagnosis of fetal

abnormality.

Reproductive

;16(sup31):82-9.

health

matters.

Geressu T, Gebrehiwot Y, Edelman A. Second-trimester

abortion: current practices and barriers to service in

Ethiopia. IPAS; 2010.

Henshaw SK. Factors hindering access to abortion

services. Family planning perspectives. 1995:54-87.

Rosenfield A. The difficult issue of second-trimester

abortion. Mass Medical Soc; 1994. p. 324-5.

Dalvie SS. Second trimester abortions in India.

Reproductive Health Matters. 2008;16(sup31):37

Ingham R, Lee E, Clements SJ an and Stone N. Reasons

for second trimester abortions in England and Wales.

Reproductive health matters. 2008;16(sup31):18-29.

Gebreselassie H, Gallo MF, Monyo A, Johnson BR. The

magnitude of abortion complications in Kenya.

BJOG: An International Journal of Obstetrics &

Gynaecology. 2005;112(9):1229-35.

Senbeto E, Alene GD, Abesno N, Yeneneh H. Prevalence

and associated risk factoprs of Induced Abortion in

Northwet Ethiopia. Ethiopian Journal of health

development. 2005;19(1):37-44.

Siraneh Y and Workneh A. Determinants and outcome of

safe second trimester medical abortion at Jimma

University Medical Center, southwest Ethiopia.

Journal of pregnancy. 2019;2019(1):4513827.

Grimes DA. The continuing need for late abortions.

JAMA. 1998;280(8):747-50.

Abebe M, Mersha A, Degefa N, Molla W, Wudneh A.

Magnitude of second-trimester-induced abortion and

associated factors among women who received

abortion service at public hospitals of Arba Minch

and Wolayita Sodo towns, southern Ethiopia: A

cross-sectional study. Frontiers in global women's

health. 2022;3:969310.

Tariku M. Magnitude of Severe Acute Maternal

Morbidity and Associated Factors Related to

Abortion: A Cross‐Sectional Study in Hawassa

University Comprehensive Specialized Hospital,

Ethiopia, 2019. BioMed Research International.

;2020(1):1781652.

Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA,

Whitehead S and Atrash HK. Risk factors for legal

induced abortion–related mortality in the United

States. Obstetrics & gynecology. 2004;103(4):729

FIGO. Mifepristone & Misoprostol and Misoprostol Only

Dosing. 2023.

Wildschut H, Both MI, Medema S, Thomee E, Wildhagen

MF, Kapp N. Medical methods for mid‐trimester

termination of pregnancy. Cochrane Database of

Systematic Reviews. 2011(1).

FDRE-FHD. Technical and procedural guidline for safe

abortion service in Ethiopia. second edition ed. Addis

Abeba: FDRE-FHD; 2013 G.C.

Constant D, Harries J, Malaba T, Myer L, Patel M, Petro

G and Grossman D. Clinical outcomes and women’s

experiences before and after the introduction of

mifepristone into second-trimester medical abortion

services in South Africa. PLoS One.

;11(9):e0161843.

Jahromi AR, Rahmanian V, Taghizadeh H and

Zareibabaarabi Z. A comparison of misoprostol with

and without methylergometrine and oxytocin in

outpatient medical abortion: a phase III randomized

controlled trial. BMC Research Notes.

;16(1):257.

Borgatta L and Kapp N. Clinical guidelines. Labor

induction abortion in the second trimester.

Contraception. 2011;84(1):4-18.

Ngai SW, Tang OS and Ho PC. Randomized comparison

of vaginal (200 μg every 3 h) and oral (400 μg every

h) misoprostol when combined with mifepristone

in termination of second trimester pregnancy. Human

Reproduction. 2000;15(10):2205-8.

Lerma K and Shaw KA. Update on second trimester

medical abortion. Current Opinion in Obstetrics and

Gynecology. 2017;29(6):413-8.

IPAS. Clinical Updates in Reproductive Health. IPAS;

September 29, 2022.

Wisanumahimachai V, Pongsatha S, Chatchawarat L and

Tongsong T. Risk Factors for Failure of Second

Trimester Termination with Misoprostol as a Single

Agent. Journal of Clinical Medicine.

;13(17):5332.

Louie KS, Chong E, Tsereteli T, Avagyan G, Abrahamyan

R and Winikoff B. Second trimester medical

abortion with mifepristone followed by unlimited

dosing of buccal misoprostol in Armenia. The

European Journal of Contraception & Reproductive

Health Care. 2017;22(1):76-80.

Shaw KA, Topp NJ, Shaw JG and Blumenthal PD.

Mifepristone–misoprostol dosing interval and effect

on induction abortion times: a systematic review.

Obstetrics & Gynecology. 2013;121(6):1335-47.

Creinin MD, Fox MC, Teal S, Chen A, Schaff EA and

Meyn LA. A randomized comparison of misoprostol

to 8 hours versus 24 hours after mifepristone for

abortion. Obstetrics and gynecology. 2004;103(5 Pt

:851-9.

Hou S, Zhang L, Chen Q, Fang A and Cheng L. One-and

two-day mifepristone–misoprostol intervals for

second trimester termination of pregnancy between

and 16 weeks of gestation. International Journal

of Gynecology & Obstetrics. 2010;111(2):126-30.

Elami-Suzin M, Freeman MD, Porat N, Rojansky N,

Laufer N and Ben-Meir A. Mifepristone followed by

misoprostol or oxytocin for second-trimester

abortion: a randomized controlled trial. Obstetrics &

Gynecology. 2013;122(4):815-20.

Kahsay O. Effectiveness of mifeprostone-misoprostole

combination in second trimester termination of

pregnancy in Saint Paul’s Hospital Millennium

Medical College, Addis Ababa, Ethiopia 2018.

Abbas DF, Blum J, Ngoc NTN, Nga NTB, Chi HTK,

Martin R and Winikoff B. Simultaneous

administration

compared

with

a

-hour

mifepristone–misoprostol interval in second

trimester abortion: a randomized controlled trial.

Obstetrics & Gynecology. 2016;128(5):1077-83.

Gemzell-Danielsson K and Lalitkumar S. Second

trimester medical abortion with mifepristone

misoprostol and misoprostol alone: a review of

methods and management. Reproductive health

matters. 2008;16(31):162-72.

Mentula M. Second trimester medical termination of

pregnancy: procedure, immediate complications and

the risk of repeat termination. 2012.

Reischer T, Limbach I, Catic A, Niedermaier K, Falcone

V and Yerlikaya-Schatten G. Factors influencing the

duration of termination of pregnancy for fetal

anomaly with mifepristone in combination with

misoprostol.

Journal

;12(3):869.

of

Clinical

Medicine.

Kapp N, Borgatta L, Stubblefield P, Vragovic O and

Moreno N. Mifepristone in second-trimester medical

abortion: a randomized controlled trial. Obstetrics &

Gynecology. 2007;110(6):1304-10.

SA F. Oral versus vaginal misoprostol for induction of

labour. A double-blind randomized controlled trial.

Am J Obstet Gynecol. 2001;185:906-10.

Danielsson KG, Marions L, Rodriguez A, Spur B, Wong

P, Bygdeman M. Comparison between oral and

vaginal administration of misoprostol on uterine

contractility.

Obstetrics

;93(2):275-80.

& gynecology.

Dickinson JE and Evans SF. The optimization of

intravaginal misoprostol dosing schedules in second

trimester pregnancy termination. American journal

of obstetrics and gynecology. 2002;186(3):470-4.

Gilbert A and Reid R. A randomised trial of oral versus

vaginal administration of misoprostol for the purpose

of mid‐trimester termination of pregnancy.

Australian and New Zealand Journal of Obstetrics

and Gynaecology. 2001;41(4):407-10.

Herabutya Y, Chanrachakul B, and Punyavachira P. A

randomised controlled trial of 6 and 12 hourly

administration of vaginal misoprostol for second

trimester

pregnancy termination. BJOG: An

International Journal of Obstetrics & Gynaecology.

;112(9):1297-301.

Ashok PW, Templeton A, Wagaarachchi PT and Flett G.

Midtrimester medical termination of pregnancy: a

review of 1002 consecutive cases. Contraception.

;69(1):51-8.

Dickinson JE and Doherty DA. Maternal complications

associated with second trimester medical abortion

using mifepristone priming and subsequent

misoprostol. Contraception. 2023;125.

Drey EA, Foster DG, Jackson RA, Lee SJ, Cardenas LH

and Darney PD. Risk factors associated with

presenting for abortion in the second trimester.

Obstetrics & Gynecology. 2006;107(1):128-35.

Mentula MJ, Niinimäki M, Suhonen S, Hemminki E,

Gissler M and Heikinheimo O. Immediate adverse

events after second trimester medical termination of

pregnancy: results of a nationwide registry study.

Human reproduction. 2011;26(4):927-32.

Mulat A, Bayu H, Mellie H and Alemu A. Induced second

trimester abortion and associated factors in Amhara

region

referral

hospitals.

BioMed research

international. 2015;2015(1):256534.

RCoO G. The care of women requesting induced abortion.

London: Royal College of Obstetricians and

Gynaecologists. 2004.

Awusi V, Okeleke V. Post induced abortion morbidity and

mortality in Oleh, Nigeria. Benin Journal of

Postgraduate Medicine. 2010;12(1).

Morra I, Ferrara C, Sglavo G, Sansone A, Saccone G,

Perriera L and Carlo C. Incidence of uterine rupture

in second-trimester abortion with gemeprost alone

compared to mifepristone and gemeprost.

Contraception. 2019;99(3):152-4.

Kamranpour B, Noroozi M and Bahrami M.

Psychological experiences of women with pregnancy

termination due to fetal anomalies: a qualitative

study from the perspective of women, their spouses,

and healthcare providers in Iran. Reproductive

health. 2020;17(1):109.

Ziraba AK, Izugbara C, Levandowski BA, Gebreselassie

H, Mutua M, Mohamed SF, Egesa C and Kimani

Murage EW. Unsafe abortion in Kenya: a cross

sectional study of abortion complication severity and

associated factors. BMC pregnancy and childbirth.

;15:1-11.

Platais I, Tsereteli T, Maystruk G, Kurbanbekova D and

Winikoff B. A prospective study of mifepristone and

unlimited dosing of sublingual misoprostol for

termination of second-trimester pregnancy in

Uzbekistan and Ukraine. BMJ Sexual &

Reproductive Health. 2019;45(3):177-82.

Jain JK and Mishell DR, Jr. A comparison of intravaginal

misoprostol with prostaglandin E2 for termination of

second-trimester pregnancy. The New England

journal of medicine. 1994;331(5):290-3.

Henkel A, Lerma K, Blumenthal PD and Shaw KA.

Evaluation of shorter mifepristone to misoprostol

intervals for second trimester medical abortion: a

retrospective

cohort

;102(5):327-31.

study.

Contraception.

Ozerkan K, Ocakoğlu G, Rehimli S, Uncu G and

Develioğlu OA comparison of low-dose and high

dose protocols of vaginal misoprostol for second

trimester termination of pregnancy. Clinical and

experimental

obstetrics

;36(4):245-7.

& gynecology.

Calvert C, Owolabi OO, Yeung F, Pittrof R, Ganatra B,

Tunçalp Ö, Tunçalp O, Adler AJ and Filippi V. The

magnitude and severity of abortion-related morbidity

in settings with limited access to abortion services: a

systematic review and meta-regression. BMJ global

health. 2018;3(3):e000692.

Owolabi OO, Cresswell JA, Vwalika B, Osrin D and

Filippi V. Incidence of abortion-related near-miss

complications in Zambia: cross-sectional study in

Central,

Copperbelt and Lusaka Provinces.

Contraception. 2017;95(2):167-74.

Arena A, Moro E, Degli Esposti E, Zanello M, Lenzi J,

Casadio P, Seracchioli R, Perrone A and Lenzi M.

How much will it hurt? Factors associated with pain

experience in women undergoing medication

abortion during the first trimester. Contraception.

;119:109916.

Nijman TA, Voogdt KG, Teunissen PW, van der Voorn PJ,

de Groot CJ ND Bakker PC. Association between

infection and fever in terminations of pregnancy

using misoprostol: a retrospective cohort study.

BMC pregnancy and childbirth. 2017;17:1-7.

Refbacks

  • There are currently no refbacks.